1.Vander CB, Muñoz-Gomariz E, Font P, Mulero J, De VK, Boonen A, et al. Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery. Rheumatology. 2010;49(1):73–81.
2.Wink F, Arends S, Maas F, Bootsma H, Griep EN, Bruyn GAW, et al. High prevalence of hip involvement and decrease in inflammatory ultrasound lesions during tumour necrosis factor-alpha blocking therapy in ankylosing spondylitis. Rheumatology (Oxford, England). 2019;58(6):1040–6.
3.Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis & Rheumatology. 2016;68(2):282–98.
4.Jia L, Zhao J, He C, Tong W, Zou Y, Xu W. Comparison of Blood Loss After Total Hip Arthroplasty Between Ankylosing Spondylitis and Osteoarthritis. Journal of Arthroplasty. 2016;31(7):1504–9.
5.Spahn DR. Anemia and patient blood management in hip and knee surgery: a systematic review of the literature. Anesthesiology. 2010;113(2):482–95.
6.Guan M, Wang J, Zhao L, Xiao J, Li Z, Shi Z. Management of hip involvement in ankylosing spondylitis. Clinical Rheumatology. 2013;32(8):1115–20.
7.Fraval A, Effeney P, Fiddelaers L, Smith B, Towell B, Tran P. OBTAIN A: Outcome Benefits of Tranexamic Acid in Hip Arthroplasty. A Randomized Double-Blinded Controlled Trial. The Journal of arthroplasty. 2017;32(5):1516–9.
8.Kayupov E, Fillingham YA, Okroj K, Plummer DR, Moric M, Gerlinger TL, et al. Oral and Intravenous Tranexamic Acid Are Equivalent at Reducing Blood Loss Following Total Hip Arthroplasty: A Randomized Controlled Trial. The Journal of bone and joint surgery American volume. 2017;99(5):373–8.
9.Meermans G, Konan S, Das R, Volpin A, Haddad FS. The direct anterior approach in total hip arthroplasty: a systematic review of the literature. The bone & joint journal. 2017;99-B(6):732–40.
10.Aissaoui N, Rostom S, Hakkou J, Berrada Ghziouel K, Bahiri R, Abouqal R, et al. Fatigue in patients with ankylosing spondylitis: prevalence and relationships with disease-specific variables, psychological status, and sleep disturbance. Rheumatol Int. 2012;32(7):2117–24.
11.Sağ S, Nas K, Serdar Sağ M, Tekeoğlu I, Kamanli A. Relationship of work disability between the disease activity, depression and quality of life in patients with ankylosing spondylitis2018. 1–7 p.
12.Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis. 2011;70(11):1921–5.
13.Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Seminars in arthritis and rheumatism. 2004;34(3):585–92.
14.So AK, Varisco PA, Kemkesmatthes B, Herkennemorard C, Chobazpéclat V, Gerster JC, et al. Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. Journal of Thrombosis and Haemostasis. 2003;1(12):2510–5.
15.van Eijk IC, Peters MJ, Serne EH, van der Horst-Bruinsma IE, Dijkmans BA, Smulders YM, et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann Rheum Dis. 2009;68(3):362–6.
16.Arends S, Spoorenberg A, Brouwer E, van der Veer E. Clinical studies on bone-related outcome and the effect of TNF-alpha blocking therapy in ankylosing spondylitis. Current opinion in rheumatology. 2014;26(3):259–68.
17.Geusens P, Vosse D, van der Linden S. Osteoporosis and vertebral fractures in ankylosing spondylitis. Current opinion in rheumatology. 2007;19(4):335–9.
18.Klingberg E, Lorentzon M, Mellstrom D, Geijer M, Gothlin J, Hilme E, et al. Osteoporosis in ankylosing spondylitis - prevalence, risk factors and methods of assessment. Arthritis research & therapy. 2012;14(3):R108.
19.Singh M, Nagrath AR, Maini P. Changes in trabecular pattern of the upper end of the femur as an index of osteoporosis. JBJS. 1970;52(3):457–67.
20.Murphy M, Wallington T, Kelsey P, Boulton F, Bruce M, Cohen H, et al. Guidelines for the clinical use of red cell transfusions. British journal of haematology. 2001;113(1):24.
21.Rosencher N, Kerkkamp HE, Macheras G, Munuera LM, Menichella G, Barton DM, et al. Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe. Transfusion. 2003;43(4):459–69.
22.Martinez V, Monsaingeonlion A, Cherif K, Judet T, Chauvin M, Fletcher D. Transfusion strategy for primary knee and hip arthroplasty: impact of an algorithm to lower transfusion rates and hospital costs. Human Reproduction. 1994;9(7):1297–9.
23.Van dHD, Lie E, Kvien TK, Sieper J, Van dBF, Listing J, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases. 2009;68(12):1811–8.
24.Zhao J, Li J, Zheng W, Liu D, Sun X, Xu W. Low Body Mass Index and Blood Loss in Primary Total Hip Arthroplasty: Results from 236 Consecutive Ankylosing Spondylitis Patients. Biomed Research International. 2014;2014(1):971–5.
25.Madjdpour C, Spahn DR. Allogeneic red blood cell transfusions: efficacy, risks, alternatives and indications. British Journal of Anaesthesia. 2005;95(1):33–42.
26.Beinsberger J, Heemskerk JW, Cosemans JM. Chronic arthritis and cardiovascular disease: altered blood parameters give rise to a prothrombotic propensity. Seminars in arthritis and rheumatism. 2014;44(3):345–52.
27.Prati C, Racadot E, Cedoz JP, Wendling D. Thrombin generation in ankylosing spondylitis. Clinical Rheumatology. 2011;30(4):511–4.
28.Wolfe F, Michaud K. Anemia and renal function in patients with rheumatoid arthritis. Journal of Rheumatology. 2006;33(8):1516–22.
29.Braun J, Van dHD, Doyle MK, Han C, Deodhar A, Inman R, et al. Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab. Arthritis Care & Research. 2009;61(8):1032–6.
30.Bal A, Unlu E, Bahar G, Aydog E, Eksioglu E, Yorgancioglu R. Comparison of serum IL–1 beta, sIL–2R, IL–6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clinical Rheumatology. 2007;26(2):211–5.
31.Heilig B, Pezzutto A, Lukoschek M, Hunstein W. [Expression of TNF receptors in rheumatoid arthritis and ankylosing spondylitis]. Zeitschrift fur Rheumatologie. 1993;52(6):383–9.
32.Martindale J, Smith J, Sutton CJ, Grennan D, Goodacre L, Goodacre JA. Disease and psychological status in ankylosing spondylitis. Rheumatology (Oxford, England). 2006;45(10):1288–93.
33.Capaci K, Hepguler S, Argin M, Tas I. Bone mineral density in mild and advanced ankylosing spondylitis. Yonsei medical journal. 2003;44(3):379–84.
34.van der Weijden MA, Claushuis TA, Nazari T, Lems WF, Dijkmans BA, van der Horst-Bruinsma IE. High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review. Clin Rheumatol. 2012;31(11):1529–35.
35.El Maghraoui A, Borderie D, Cherruau B, Edouard R, Dougados M, Roux C. Osteoporosis, body composition, and bone turnover in ankylosing spondylitis. The Journal of rheumatology. 1999;26(10):2205–9.
36.Maillefert JF, Aho LS, El Maghraoui A, Dougados M, Roux C. Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2001;12(7):605–9.
37.Grazio S, Kusić Z, Cvijetić S, Grubišić F, Balenović A, Nemčić T, et al. Relationship of bone mineral density with disease activity and functional ability in patients with ankylosing spondylitis: A cross-sectional study2011. 2801–8 p.
38.Wang DM, Zeng QY, Chen SB, Gong Y, Hou ZD, Xiao ZY. Prevalence and risk factors of osteoporosis in patients with ankylosing spondylitis: a 5-year follow-up study of 504 cases. Clinical and experimental rheumatology. 2015;33(4):465–70.
39.Karakoc M, Altindag O, Keles H, Soran N, Selek S. Serum oxidative–antioxidative status in patients with ankylosing spondilitis. Rheumatology International. 2007;27(12):1131–4.
40.Azevedo VF, Faria-Neto JR, Stinghen A, Lorencetti PG, Miller WP, Gonçalves BP, et al. IL–8 but not other biomarkers of endothelial damage is associated with disease activity in patients with ankylosing spondylitis without treatment with anti-TNF agents. Rheumatology International. 2013;33(7):1779–83.
41.Drouart M, Saas P, Billot M, Cedoz JP, Tiberghien P, Wendling D, et al. High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies. Clinical & Experimental Immunology. 2003;132(1):158–62.
42.Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras M, Tanjong Ghogomu E, et al. TNF‐alpha inhibitors for ankylosing spondylitis. The Cochrane Library. 2015.